Released Mar 14, 2024, after the close
10-K filed Mar 14, 2024, 74 days after period end · 0001140361-24-013254
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$6.15M-$6.15M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$49,000—
Operating Incomederived-$5,765,000N/M
Operating Cash Flowderived-$4,661,000N/M
Free Cash Flowderived-$4,680,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $1.18M |
| Net Income | -$6.15M | -$4.49M | -$7.95M | -$2.22M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR